GlobeNewswire·Aug 7, 2026, 4:05 PM ET

Braveheart Bio Announces Closing of Upsized Initial Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Braveheart Bio, Inc. (NASDAQ: BRVE) closed its upsized initial public offering of 24,437,500 shares at $18.00 per share, including the full exercise of the underwriters' option to purchase 3,187,500 additional shares.
All shares were offered by Braveheart Bio & trading began on the Nasdaq Global Market on August 6, 2026, under the ticker symbol "BRVE".
The gross proceeds from the offering totaled $439.9 million before deducting underwriting discounts, commissions, & offering expenses.
Goldman Sachs & Co. LLC, Jefferies, TD Cowen, Stifel & Cantor served as joint book-running managers for the offering.
Registration statements with the U.S. Securities and Exchange Commission became effective on August 5, 2026.
Braveheart Bio is a clinical-stage biopharmaceutical company developing next-generation therapies for hypertrophic cardiomyopathy (HCM) & other cardiovascular diseases.
The company's lead product candidate is BHB-1893, a next-generation oral small-molecule cardiac myosin inhibitor being developed for obstructive & non-obstructive HCM.